## U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES
Amendment No. 20

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

July 8,	ordance with the letter	r dated			
'	2013				
2 1:000	, 20.0,				
l l	<ul><li>3. License number 13-03459-03 is amended in its entirety to read as follows:</li><li>4. Expiration date September 30, 2015</li></ul>				
4. Expira					
5. Docke	et No. 030-31379				
Refer	rence No.				
hemical and/or physical	r	Maximum amount that licensee may possess at any one time under this license			
Any	•	A. As needed			
Any		B. As needed			
Any	(	C. 0.5 curies			
Series and 6520; I	IPL Model 67-	D. One curie			
International 2300 Model Nos. 6711 a Theragenics Corp. I25.S06; IsoAid Mo Advantage IAI-125 LLC Model LS-1; In Sciences Corp. Mo North American So 3631; Bard Brachy Model STM – 1251 Trade, Inc. Model I	Series; 3M and 6702; . Model No. odel 5A; Draximage implant odel 3500; cientific Model ytherapy, Inc. 1; Bebig 125.S06;	E. 500 millicuries			
	entiret  4. Expir 5. Dock Refe hemical and/or physical  Any  Any  Sealed sources (3 Series and 6520; 800 Series and 67  Sealed sources (Enternational 2300 Model Nos. 6711 Theragenics Corp I25.S06; IsoAid M Advantage IAI-125 LLC Model LS-1; I Sciences Corp. M North American S 3631; Bard Brachy Model STM — 125 Trade, Inc. Model Medi-Physics, Inc.	entirety to read as follows:  4. Expiration date September 3  5. Docket No. 030-31379 Reference No.  hemical and/or physical form  8. If  Any  Any  Sealed sources (3M Model 6500 Series and 6520; IPL Model 67- 800 Series and 67-820 Series)  Sealed sources (Best Medical International 2300 Series; 3M Model Nos. 6711 and 6702; Theragenics Corp. Model No. I25.S06; IsoAid Model Advantage IAI-125A; Draximage LLC Model LS-1; Implant Sciences Corp. Model 3500; North American Scientific Model 3631; Bard Brachytherapy, Inc. Model STM — 1251; Bebig Trade, Inc. Model 125.S06; Medi-Physics, Inc. Model 6733			

N	RC FC	ORM 374A	U.S. NUCLEAR R	EGULAT	ORY COMMISSION		PAG	GE	2	of	4	PAGES
			MATERIALS LICE SUPPLEMENTARY S			License Number 13-03459-03 Docket or Reference Numbe 030-31379						
						Amendment No. 20						
-	F.	Palladium 10 CFR 3	m-103 permitted by 35.400	F.	Sealed sources International 230 Theragenics Cor 200; IsoAid Mod IAPd-103A; Nort Scientific Model International Bra Model 1032p Op	00 Series; orp. Model No. del Advantage th American 3633; achytherapy, Inc.	F.	500	0 mi	illicur	ries	
	G.	Cesium-1 CFR 35.4	131 permitted by 10 400	G.	Sealed sources of International 230 IsoRay, Inc. Mod	00 Series and	G.	50	)0 m	nillicu	ries	
	H.	Samariun 10 CFR 3	m-145 permitted by 35.400	H.	Sealed sources ( International 230	•	H.	50	)0 m	nillicu	ries	
	I.	Iridium-19 CFR 35.4	92 permitted by 10 400	I.	Sealed sources ( International Mod Series)		l.	On	ne cu	rie		
	J.	, ,	oduct material I by 10 CFR 31.11	J.	.Prepackaged Kits	; ;	J.	3 n	nillic	curies	3	
9.	9. Authorized use:											
	A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.											
	B. Any imaging and localization study permitted by 10 CFR 35.200.											
	C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.											
	D. through I., inclusive: Any manual brachytherapy procedure permitted by 10 CFR 35.400.											
	J. In vitro studies.											
CONDITIONS												

- 10. Licensed material may be used or stored at the licensee's facilities located at 1500 South Lake Park Avenue, Hobart, Indiana.
- 11. The Radiation Safety Officer for this license is James C. Hatten.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	3	of	4	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number 13-03459-03 Docket or Reference Number 030-31379	er				
		Amendment No. 20					

- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Jong-Yuan Kuo, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Mikhail Jeha, M.D.	10 CFR 35.100 and 35.200.
Jesse Reyes, M.D.	10 CFR 35.100 and 35.200.
Koppolu P. Sarma, M.D.	10 CFR 35.300 (for palliative treatment of bone pain using strontium-89) and 35.400.
Kamala Modur, M.D.	10 CFR 35.400.
Erlinda Roque-Kerekas, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Jeffrey Jon Quackenbush, M.D.	10 CFR 35.300 and 35.400.
Shawn R. Kenney, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
Jonathon T. Lee, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
Francis X. Roche, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Thomas M. Hoess, M.D. Vijah P. Shah, M.D. Harish Shah, M.D. Kais J. Yehyawi, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11. 10 CFR 35.100 and 35.200. 10 CFR 35.100 and 35.200. 10 CFR 35.100 and 35.200.
Abdul Kawamleh, M.D.	10 CFR 35.100 and 35.200.

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

- 14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee=s ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Application dated July 19, 2005; and,
  - B. Letters dated October 9, 2006, November 9, 2006, January 2, 2009, January 18, 2010, March 8, 2010, January 22, 2013, (with attachment), March 18, 2013 (pertaining to RSO change), March 18, 2013, (limited to phase I approval for renovations, release of nuclear medicine department for unrestricted use and addition of renovated spaces), June 7, 2013 (with attachments), and July 8, 2013 (with attachments).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

JUL 1 1 2013

У \_\_\_\_

Colleen Carol Casev

Materials Licensing Branch

Region III